Anna E Coghill1,2, Xuesong Han3, Gita Suneja4, Chun Chieh Lin3,5, Ahmedin Jemal3, Meredith S Shiels1. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. 2. Cancer Epidemiology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 3. Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia. 4. Radiation Oncology, Duke University, Durham, North Carolina. 5. Health Services Research Program, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: People living with HIV (PLWH) are at an increased risk of developing several cancers, but to the authors' knowledge less is known regarding how HIV impacts the rate of progression to advanced cancer or death. METHODS: The authors compared stage of disease at the time of presentation and mortality after diagnosis between 14,453 PLWH and 6,368,126 HIV-uninfected patients diagnosed with cancers of the oral cavity, stomach, colorectum, anus, liver, pancreas, lung, female breast, cervix, prostate, bladder, kidney, and thyroid and melanoma using data from the National Cancer Data Base (2004-2014). Polytomous logistic regression and Cox proportional hazards regression were used to evaluate the association between HIV, cancer stage, and stage-adjusted mortality after diagnosis, respectively. Regression models accounted for the type of health facility at which cancer treatment was administered and the type of individual health insurance. RESULTS: HIV-infected patients with cancer were found to be more likely to be uninsured (HIV-infected: 5.0% vs HIV-uninfected: 3.3%; P < .0001) and were less likely to have private health insurance (25.4% vs 44.7%; P < .0001). Compared with those not infected with HIV, the odds of being diagnosed at an advanced stage of disease were significantly elevated in PLWH for melanoma and cancers of the oral cavity, liver, female breast, prostate, and thyroid (odds ratio for stage IV vs stage I range, 1.24-2.06). PLWH who were diagnosed with stage I to stage III disease experienced elevated mortality after diagnosis across 13 of the 14 cancer sites evaluated, with hazard ratios ranging from 1.20 (95% CI, 1.14-1.26) for lung cancer to 1.85 (95% CI, 1.68-2.04), 1.85 (95% CI, 1.51-2.27), and 2.93 (95% CI, 2.08-4.13), respectively, for cancers of the female breast, cervix, and thyroid. CONCLUSIONS: PLWH were more likely to be diagnosed with advanced-stage cancers and to experience elevated mortality after a cancer diagnosis, even after accounting for health care-related factors.
BACKGROUND:People living with HIV (PLWH) are at an increased risk of developing several cancers, but to the authors' knowledge less is known regarding how HIV impacts the rate of progression to advanced cancer or death. METHODS: The authors compared stage of disease at the time of presentation and mortality after diagnosis between 14,453 PLWH and 6,368,126 HIV-uninfectedpatients diagnosed with cancers of the oral cavity, stomach, colorectum, anus, liver, pancreas, lung, female breast, cervix, prostate, bladder, kidney, and thyroid and melanoma using data from the National Cancer Data Base (2004-2014). Polytomous logistic regression and Cox proportional hazards regression were used to evaluate the association between HIV, cancer stage, and stage-adjusted mortality after diagnosis, respectively. Regression models accounted for the type of health facility at which cancer treatment was administered and the type of individual health insurance. RESULTS:HIV-infectedpatients with cancer were found to be more likely to be uninsured (HIV-infected: 5.0% vs HIV-uninfected: 3.3%; P < .0001) and were less likely to have private health insurance (25.4% vs 44.7%; P < .0001). Compared with those not infected with HIV, the odds of being diagnosed at an advanced stage of disease were significantly elevated in PLWH for melanoma and cancers of the oral cavity, liver, female breast, prostate, and thyroid (odds ratio for stage IV vs stage I range, 1.24-2.06). PLWH who were diagnosed with stage I to stage III disease experienced elevated mortality after diagnosis across 13 of the 14 cancer sites evaluated, with hazard ratios ranging from 1.20 (95% CI, 1.14-1.26) for lung cancer to 1.85 (95% CI, 1.68-2.04), 1.85 (95% CI, 1.51-2.27), and 2.93 (95% CI, 2.08-4.13), respectively, for cancers of the female breast, cervix, and thyroid. CONCLUSIONS: PLWH were more likely to be diagnosed with advanced-stage cancers and to experience elevated mortality after a cancer diagnosis, even after accounting for health care-related factors.
Authors: L P Jacobson; T E Yamashita; R Detels; J B Margolick; J S Chmiel; L A Kingsley; S Melnick; A Muñoz Journal: J Acquir Immune Defic Syndr Date: 1999-08-01 Impact factor: 3.731
Authors: Chun Chao; Lanfang Xu; Donald Abrams; Wendy Leyden; Michael Horberg; William Towner; Daniel Klein; Beth Tang; Michael Silverberg Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar Journal: AIDS Date: 2006-08-01 Impact factor: 4.177
Authors: Eric A Engels; Robert J Biggar; H Irene Hall; Helene Cross; Allison Crutchfield; Jack L Finch; Rebecca Grigg; Tara Hylton; Karen S Pawlish; Timothy S McNeel; James J Goedert Journal: Int J Cancer Date: 2008-07-01 Impact factor: 7.396
Authors: Mohamed A Eltom; Ahmedin Jemal; Sam M Mbulaiteye; Susan S Devesa; Robert J Biggar Journal: J Natl Cancer Inst Date: 2002-08-21 Impact factor: 13.506
Authors: Jessie Torgersen; Tamar H Taddei; Lesley S Park; Dena M Carbonari; Michael J Kallan; Kisha Mitchell Richards; Xuchen Zhang; Darshana Jhala; Norbert Bräu; Robert Homer; Kathryn D'Addeo; Rajni Mehta; Melissa Skanderson; Farah Kidwai-Khan; Amy C Justice; Vincent Lo Re Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-10-01 Impact factor: 4.254
Authors: Michael S Leapman; Kimberly Stone; Roxanne Wadia; Lesley S Park; Cynthia L Gibert; Matthew B Goetz; Roger Bedimo; Maria Rodriguez-Barradas; Fatma Shebl; Amy C Justice; Sheldon T Brown; Kristina Crothers; Keith M Sigel Journal: J Urol Date: 2021-09-24 Impact factor: 7.600
Authors: Keri L Calkins; Geetanjali Chander; Corinne E Joshu; Kala Visvanathan; Anthony T Fojo; Catherine R Lesko; Richard D Moore; Bryan Lau Journal: Cancer Causes Control Date: 2020-03-06 Impact factor: 2.506
Authors: Yoanna S Pumpalova; Oluwatosin A Ayeni; Wenlong Carl Chen; Daniel S O'Neil; Sarah Nietz; Boitumelo Phakathi; Ines Buccimazza; Sharon Čačala; Laura W Stopforth; Hayley A Farrow; Maureen Joffe; Witness Mapanga; Judith S Jacobson; Katherine D Crew; Herbert Cubasch; Paul Ruff; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2021-06-14 Impact factor: 4.624
Authors: Sarah Nietz; Daniel S O'Neil; Oluwatosin Ayeni; Wenlong Carl Chen; Maureen Joffe; Judith S Jacobson; Alfred I Neugut; Paul Ruff; Witness Mapanga; Ines Buccimazza; Urishka Singh; Sharon Čačala; Laura Stopforth; Boitumelo Phakathi; Tobias Chirwa; Herbert Cubasch Journal: Breast Cancer Res Treat Date: 2020-09-01 Impact factor: 4.872